795 related articles for article (PubMed ID: 25600098)
1. The microbiome of the urinary tract--a role beyond infection.
Whiteside SA; Razvi H; Dave S; Reid G; Burton JP
Nat Rev Urol; 2015 Feb; 12(2):81-90. PubMed ID: 25600098
[TBL] [Abstract][Full Text] [Related]
2. Re: The Microbiome of the Urinary Tract--A Role Beyond Infection.
Wein AJ
J Urol; 2015 Dec; 194(6):1643-4. PubMed ID: 26582671
[No Abstract] [Full Text] [Related]
3. The Urinary Microbiome: Implications in Bladder Cancer Pathogenesis and Therapeutics.
Bajic P; Wolfe AJ; Gupta GN
Urology; 2019 Apr; 126():10-15. PubMed ID: 30615894
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
[TBL] [Abstract][Full Text] [Related]
5. Is there a link between urinary microbiota and bladder cancer?
Raoult D
Eur J Epidemiol; 2017 Mar; 32(3):255. PubMed ID: 28013490
[No Abstract] [Full Text] [Related]
6. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
McHugh LA; Griffiths TR
BJU Int; 2004 Jul; 94(1):193. PubMed ID: 15217467
[No Abstract] [Full Text] [Related]
7. Bladder cancer: Always consider extravesical sites when BCG fails.
von Rundstedt FC; Lerner SP
Nat Rev Urol; 2014 Jan; 11(1):11-2. PubMed ID: 24346003
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Taylor JH; Davis J; Schellhammer P
Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
[TBL] [Abstract][Full Text] [Related]
9. The Microbiome and Genitourinary Cancer: A Collaborative Review.
Markowski MC; Boorjian SA; Burton JP; Hahn NM; Ingersoll MA; Maleki Vareki S; Pal SK; Sfanos KS
Eur Urol; 2019 Apr; 75(4):637-646. PubMed ID: 30655087
[TBL] [Abstract][Full Text] [Related]
10. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
11. The Urinary Tract Microbiome in Health and Disease.
Aragón IM; Herrera-Imbroda B; Queipo-Ortuño MI; Castillo E; Del Moral JS; Gómez-Millán J; Yucel G; Lara MF
Eur Urol Focus; 2018 Jan; 4(1):128-138. PubMed ID: 28753805
[TBL] [Abstract][Full Text] [Related]
12. Urobiome: An outlook on the metagenome of urological diseases.
Shoemaker R; Kim J
Investig Clin Urol; 2021 Nov; 62(6):611-622. PubMed ID: 34729961
[TBL] [Abstract][Full Text] [Related]
13. The human urinary microbiome and how it relates to urogynecology.
Schneeweiss J; Koch M; Umek W
Int Urogynecol J; 2016 Sep; 27(9):1307-12. PubMed ID: 26811114
[TBL] [Abstract][Full Text] [Related]
14. [International Consensus Panel--treatment strategies for superficial bladder cancer].
Adler S; St Niclas M
Aktuelle Urol; 2006 Sep; 37(5):320-3; discussion 322-3. PubMed ID: 17004179
[No Abstract] [Full Text] [Related]
15. [Review of the value of BCG maintenance therapy in superficial bladder tumours].
Peyromaure M; Zerbib M
Prog Urol; 2004 Feb; 14(1):105-8. PubMed ID: 15098767
[TBL] [Abstract][Full Text] [Related]
16. Pure squamous cell carcinoma after intravesical BCG treatment. A case report.
Yurdakul T; Avunduk MC; Piskin MM
Urol Int; 2005; 74(3):283-5. PubMed ID: 15812221
[TBL] [Abstract][Full Text] [Related]
17. Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer.
Bochner BH
Nat Clin Pract Oncol; 2006 Sep; 3(9):474-5. PubMed ID: 16955082
[No Abstract] [Full Text] [Related]
18. Meta-analysis of Clinical Microbiome Studies in Urolithiasis Reveal Age, Stone Composition, and Study Location as the Predominant Factors in Urolithiasis-Associated Microbiome Composition.
Kachroo N; Lange D; Penniston KL; Stern J; Tasian G; Bajic P; Wolfe AJ; Suryavanshi M; Ticinesi A; Meschi T; Monga M; Miller AW
mBio; 2021 Aug; 12(4):e0200721. PubMed ID: 34372696
[TBL] [Abstract][Full Text] [Related]
19. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
Leibovici D; Zisman A; Lindner A
Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
[No Abstract] [Full Text] [Related]
20. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
